Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors

Publisher： Karger

E-ISSN： 1421-9875|34|6|714-730

ISSN： 0257-2753

Source： Digestive Diseases, Vol.34, Iss.6, 2016-10, pp. : 714-730

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immune Checkpoint Blockade in Hepatocellular Carcinoma

By  

Liver Cancer, Vol. 4, Iss. 4, 2015-0 ,pp. : 201-207

Karger

Access to resources Recommend Favorite

Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma

By  

Liver Cancer, Vol. 5, Iss. 4, 2016-09 ,pp. : 235-244

Karger

Access to resources Recommend Favorite

Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update

By  

Liver Cancer, Vol. 6, Iss. 1, 2016-11 ,pp. : 1-12

Karger

Access to resources Recommend Favorite

Recent Progress in the Treatment and Diagnosis of Hepatocellular Carcinoma

By  

Liver Cancer, Vol. 2, Iss. 1, 2013-01 ,pp. : 4-4

Karger

Access to resources Recommend Favorite

A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib

By  

Liver Cancer, Vol. 6, Iss. 3, 2017-03 ,pp. : 177-184

Karger

Access to resources Recommend Favorite